Sionna Therapeutics (NASDAQ:SION) Trading 8.8% Higher – Time to Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price shot up 8.8% on Tuesday . The company traded as high as $39.70 and last traded at $39.8960. 76,306 shares traded hands during trading, a decline of 73% from the average session volume of 287,266 shares. The stock had previously closed at $36.66.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SION shares. Guggenheim boosted their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Monday, March 2nd. Citizens Jmp began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.57.

Sionna Therapeutics Price Performance

The business’s fifty day moving average price is $37.93 and its 200-day moving average price is $36.99. The stock has a market capitalization of $1.83 billion and a PE ratio of -20.83.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15.

Insider Activity

In other news, Director Peter A. Thompson sold 29,063 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the transaction, the director owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. This represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 29,063 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54. Following the completion of the sale, the director owned 3,530,702 shares in the company, valued at $157,398,695.16. This trade represents a 0.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 311,906 shares of company stock worth $12,759,732 in the last three months. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Large investors have recently modified their holdings of the business. Invesco Ltd. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth about $4,573,000. XTX Topco Ltd purchased a new stake in Sionna Therapeutics in the fourth quarter valued at approximately $203,000. Superstring Capital Management LP bought a new stake in Sionna Therapeutics during the fourth quarter valued at approximately $7,430,000. Artia Global Partners LP purchased a new position in Sionna Therapeutics in the 4th quarter worth approximately $4,926,000. Finally, Balyasny Asset Management L.P. purchased a new position in Sionna Therapeutics in the 4th quarter worth approximately $58,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.